Coronary disease & ACSCohort study
Triglyceride reduction after myocardial infarction (MI) and major adverse outcomes in SWEDEHEART—insights for future trials
- Registry-based cohort study
- SWEDEHEART registry
- adjusted Cox models
Authors' conclusion
Among MI patients, triglyceride reductions of ∼1.0 mmol/L were associated with the lowest cardiovascular risk. Only 27% of patients achieved this reduction with baseline triglycerides ∼2.2 mmol/L.
Study context
- Population
- MI patients in the Swedish MI registry SWEDEHEART, 2005–2022
- Participants
- 51,719 patients
- Exposure
- Triglyceride change from admission to 1 year vs minimal change
- Outcome
- MACE (all-cause mortality, non-fatal MI, non-fatal ischaemic stroke), all-cause mortality and non-fatal MI
Main finding
As reported in the abstract
MACE, all-cause mortality, non-fatal MI
Top quartile of TG reduction vs Minimal changeHR
MACE
0.85(95% CI 0.79–0.92)
all-cause mortality
0.90(CI 0.81–0.99)
non-fatal MI
0.83(CI 0.74–0.94)
Observational data: associations, not effects.
Further findings
Median TG levels, all patients
mmol/L
- Median TG at MI admission
- 1.4 (IQR 1.0-2.0)
- Median TG at 1 year
- 1.2 (0.9-1.6)
- Baseline TG, top quartile of reduction
- 2.2 (1.8-2.9)
Cardiovascular risk by 1-year TG level
- Lowest quartile at 1 year (<0.9 mmol/L) had the lowest cardiovascular risk
Original publication
Triglyceride reduction after MI and major adverse outcomes in SWEDEHEART—insights for future trials. Eur J Prev Cardiol. Published 19 February 2026. doi:10.1093/eurjpc/zwag076
Summarised from the published abstract; every number is checked against it